Fayetteville, AR

At the Al Khamsa Annual Meeting and Convention  today in Fayetteville, Arkansas, EquiSeq announced that it has added the P8 and K1 tests to the Myopathy Panel at no extra cost. EquiSeq’s Myopathy Panel, priced at $249, now includes tests for P2, P3, P4, Px, P8, and K1.

The P8 and K1 genetic variants are missense alleles of undisclosed genes of known function. P8 and K1 are known to be pathogenic as a result of EquiSeq’s internal validation process. The genes will be disclosed in a peer-reviewed scientific publication.

The P8 genetic variant is prevalent in Arabians, but has also be found in Thoroughbreds, stock breeds (Quarter Horses, Paints, and Appaloosas), Icelandics, and other breeds.

The K1 genetic variant is prevalent in Arabians, but has also been found in Morgans, American Miniatures, Haflingers, and Standardbreds. It is rare in stock breeds (Quarter Horses, Paints, and Appaloosas) and appears to be absent in Thoroughbreds.

Tests for the P8 and K1 genetic variants will be included at no extra cost in EquiSeq’s Myopathy Panel through January 31, 2020. After that, the price of the Myopathy Panel will increase to $299.